minoxidil oral solution (N1087) / Eurofarma - LARVOL DELTA

Alopecia management from a comparative perspective: pharmacological and pharmaceutical insights in humans, dogs, and cats. (PubMed, Front Vet Sci) - "In humans, United States Food and Drug Administration-approved treatments, including topical minoxidil, oral finasteride, and selected Janus kinase inhibitors, are supplemented by emerging approaches such as platelet-rich plasma, low-level laser therapy, regenerative medicine, and nanotechnology-based delivery systems. Dermatophytosis further illustrates the One Health relevance of comparative alopecia management because successful control may require coordinated treatment of affected animals and humans together with environmental decontamination. This review highlights the need for species-specific clinical trials, safety assessment, and formulation strategies to support the development of effective and practical treatments for human and veterinary alopecia."

Journal • Review • Alopecia • Dermatology • Immunology

Pain in the heart, hair on the head: Pericarditis as an unanticipated risk of low-dose oral minoxidil. (PubMed, JAAD Case Rep) - No abstract available

Journal • Alopecia • Cardiovascular • Pain

Assessing the Efficacy of Multimodal Therapy in Nonsurgical Hair Restoration for Noncicatricial Alopecia: A Retrospective Study. (PubMed, Plast Reconstr Surg Glob Open) - "Multimodal therapy in hair restoration represents a sophisticated amalgamation of cutting-edge treatments, including autologous multispin platelet-rich plasma, topical minoxidil, oral finasteride, correction of nutritional deficiencies, hormonal treatments, and lifestyle modifications. These data underscore the substantial benefits of multimodal therapy in hair restoration, particularly for individuals with androgenetic alopecia and other noncicatricial forms of hair loss. This integrative approach demonstrates safety and efficacy for enhanced management of hair loss."

Journal • Retrospective data • Alopecia • Immunology

Combination of Minoxidil and Herbal Extract Significantly Decreases SRD5A2 and Pro-inflammatory Cytokines in HaCaT Cells (EADV-Sp 2026) - "The primary pharmaceutical agents include topical minoxidil, oral finasteride, and dutasteride...The beneficial effects of herbal extracts are likely mediated by flavonoids such as apigenin, chlorogenic acid, catechins, quercetin, and kaempferol...The combination of minoxidil and herbal extract suppressed inflammatory cytokines and the testosterone-converting enzyme SRD5A2. In the future, topical minoxidil treatments can be combined with flavonoid- rich herbal extracts for better effectiveness."

Alopecia • Immunology • Inflammation • IL1B • IL6 • SRD5A2 • TNFA

Hair Loss Treatments: A Google Trends Analysis Worldwide of the Past 5 Years (2018-2023). (PubMed, Skin Appendage Disord) - "Data generated through GT for the relative search volumes (RSVs) of the treatments-related terms were analysed: "hair loss treatment"; "minoxidil"; "oral minoxidil"; "finasteride"; "dutasteride"; "hair transplant." Analysis has been performed worldwide from July 29, 2018, to July 16, 2023...Interest in "minoxidil" has been growing since 2018, with "minoxidil oral treatment" gaining attention since 2021...We observed temporal and geographical variations in public interest in hair loss treatments. COVID-19 pandemic, differences in the prevalence of alopecia-related conditions, cultural, social influences impact search trends across countries."

Journal • Aesthetic Medicine • Alopecia • Immunology • Infectious Disease • Novel Coronavirus Disease • Transplantation

MINORA-MEN: Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia. (clinicaltrials.gov) - P3 | N=372 | Not yet recruiting | Sponsor: Eurofarma Laboratorios S.A.

New P3 trial • Alopecia • Dermatology • Immunology